Journal of Clinical Microbiology · 2011 · 55 citations · 22 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceDiagnostic MicrobiologyMedical MicrobiologyAntibiotic ResistanceAntibiotic Resistance MechanismsAntimicrobial Susceptibility TestingBacterial EpidemiologyBacterial InfectionsPathogen DetectionAntibiotic Sensitivity TestingAntibiotic Susceptibility TestingBacterial Resistance DetectionBroth MicrodilutionGlycopeptide ResistanceResistance Mechanisms In StaphylococciStaphylococcus Aureus DetectionVancomycin-intermediate Resistance
The prevalence of heterogeneous intermediate-level resistance to vancomycin (hVISA) in Staphylococcus aureus was assessed by screening a large collection of recent isolates. Susceptibility testing by the Clinical and Laboratory Standards Institute broth microdilution method and the Etest GRD (glycopeptide resistance detection) method (bioMérieux) was performed on 4,210 clinically significant S. aureus isolates obtained in 2009 from 43 U.S. centers. Isolates with Etest GRD-positive results for hVISA were evaluated further by repeat GRD testing and population analysis profiling-area under the curve (PAP-AUC) analysis. No VISA (vancomycin MIC, 4 to 8 μg/ml) or vancomycin-resistant (MIC ≥ 16 μg/ml) strains were detected. The Etest GRD screen for hVISA was initially positive for 68 isolates (1.6%; all by teicoplanin MIC ≥ 8 μg/ml at 24 or 48 h). Among those 68 isolates, 45 were reproducibly GRD positive. PAP-AUC testing confirmed only 11 isolates as hVISA (all had reproducible GRD-positive results). The 11 hVISA isolates were from nine medical centers and appeared genetically diverse (ten different PFGE types). The rates of resistance (including intermediate) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%. All hVISA isolates were susceptible to linezolid, tigecycline, and ceftaroline. Our data suggest that the overall prevalence of hVISA in the United States is low (0.3%). The hVISA isolates represented 10.5% of isolates with vancomycin MICs of 2 μg/ml and 0.1% of isolates with vancomycin MICs of 1 μg/ml. The positive predictive value of GRD Etest for hVISA was 16.2% for initial screen positive and 24.4% for reproducibly positive results.
22
Catherine Liu, Arnold S. Bayer, Sara E. Cosgrove et al. · Clinical Infectious Diseases · 2011 · 4.2K citations · Full text
Linda K. McDougal, Christine D. Steward, George Killgore et al. · Journal of Clinical Microbiology · 2003 · 1.4K citations · Full text
Duarte C. Oliveira, Hermı́nia de Lencastre · Antimicrobial Agents and Chemotherapy · 2002 · 1.3K citations · Full text